



IBA – ACQUISITION OF OWN SHARES

Immediate Release – July 9th, 2021

Louvain-la-Neuve, Belgium, July 9th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 18.793 IBA shares on Euronext Brussels in the period from June 30th, 2021 up to and including July 8th, 2021, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
30-06-21	1.215	16,48 €	16,40 €	16,54 €	20.017,13 €
<i>Bloc 30/06</i>	<i>5.000</i>	<i>16,48 €</i>	<i>16,48 €</i>	<i>16,48 €</i>	<i>82.400,00 €</i>
01-07-21	2.014	16,50 €	16,32 €	16,62 €	33.233,22 €
02-07-21	2.118	16,53 €	16,46 €	16,64 €	35.013,72 €
05-07-21	1.057	16,65 €	16,60 €	16,68 €	17.595,24 €
06-07-21	2.247	16,45 €	16,36 €	16,52 €	36.966,97 €
07-07-21	1.654	16,60 €	16,50 €	16,74 €	27.455,08 €
08-07-21	3.488	16,32 €	16,06 €	16,50 €	56.910,21 €
TOTAL	18.793	16,47 €	16,06 €	16,74 €	309.591,56 €

These transactions include the purchase of a block of 5.000 shares at a price of 16,48 EUR/share, which was executed on June 30th, 2021 at 10.32 AM on the central order book of Euronext Brussels (XBRU).

The total number of shares purchased under this program therefore amounts to 18.793. As a result, IBA SA currently holds 839.665 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,79% of its share capital.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

Press release

Inside / regulated information



IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person

IBA

Christian Matton,
Chief Legal Officer

shareholderrelations@iba-group.com